{"id":"companion-tablet","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug is developed by the Jiangsu Institute of Parasitic Diseases, a leading research institution focused on parasitic disease therapeutics. While specific molecular targets are not publicly detailed, the drug is in Phase 3 development, indicating it has demonstrated sufficient efficacy and safety in earlier trials to warrant late-stage clinical evaluation for parasitic disease indications.","oneSentence":"Companion Tablet is an antiparasitic agent developed for treatment of parasitic infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:53.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parasitic infection (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06564233","phase":"NA","title":"Supportive Care Intervention for Outpatient Stem Cell Transplant Patients","status":"RECRUITING","sponsor":"Victor Wang","startDate":"2024-10-21","conditions":"Hematopoietic Stem Cell Transplantation, Cancer","enrollment":90},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT05424042","phase":"NA","title":"Health, Aging and Later-Life Outcomes","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2022-07-05","conditions":"Aging","enrollment":90},{"nctId":"NCT07194967","phase":"NA","title":"Virtual Reality for Pain and Anxiety Relief in Labor","status":"ENROLLING_BY_INVITATION","sponsor":"University Tunis El Manar","startDate":"2025-05-01","conditions":"Labor Pain, Anxiety","enrollment":70},{"nctId":"NCT06606353","phase":"","title":"Talk-to-Jo\" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads","status":"RECRUITING","sponsor":"Olivier Beauchet","startDate":"2024-12-12","conditions":"Caregiver, Neurocognitive Disorders","enrollment":40},{"nctId":"NCT05578898","phase":"NA","title":"CLEAR Care Companion Application","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2022-08-12","conditions":"Bladder Cancer, Radical Cystectomy","enrollment":28},{"nctId":"NCT05886686","phase":"","title":"Contactless Vital Signs Measurement Study (CVMS)","status":"UNKNOWN","sponsor":"Melbourne Health","startDate":"2023-04-05","conditions":"Vital Signs, Inpatients, Hospital-at-home","enrollment":30},{"nctId":"NCT04672525","phase":"PHASE3","title":"Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","status":"RECRUITING","sponsor":"Tourcoing Hospital","startDate":"2021-11-08","conditions":"Prosthetic Infection","enrollment":436},{"nctId":"NCT01539291","phase":"PHASE3","title":"Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2012-10-03","conditions":"Chronic Lymphocytic Leukemia","enrollment":161},{"nctId":"NCT02312219","phase":"","title":"PET/CT Imaging Companion Study To ACTG A5314","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"HIV, Inflammation, Atherosclerosis","enrollment":35},{"nctId":"NCT01311687","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-03-11","conditions":"Multiple Myeloma","enrollment":455},{"nctId":"NCT03133832","phase":"PHASE3","title":"The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium","status":"UNKNOWN","sponsor":"Jiangsu Institute of Parasitic Diseases","startDate":"2017-04-10","conditions":"Schistosomiasis Haematobia","enrollment":120},{"nctId":"NCT01431547","phase":"PHASE1","title":"Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02","conditions":"Solid Tumors","enrollment":21},{"nctId":"NCT00868127","phase":"PHASE3","title":"Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":574}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":96,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chinese-made praziquantel"],"phase":"phase_3","status":"active","brandName":"Companion Tablet","genericName":"Companion Tablet","companyName":"Jiangsu Institute of Parasitic Diseases","companyId":"jiangsu-institute-of-parasitic-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Companion Tablet is an antiparasitic agent developed for treatment of parasitic infections. Used for Parasitic infection (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}